html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

CDKN2A - melanoma-pancreatic cancer syndrome ¹

This test is available for the following conditions:

Conditions > Skin > Melanoma-pancreatic cancer syndrome
Conditions > Oncogenetics > Melanoma-pancreatic cancer syndrome

This product is also part of the following panels:

Hereditary cancer panel
Mendelian inherited disorders panel
panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
panel Melanoma, extensive (CDKN2A, CDK4, MITF p.(Glu318Lys), BAP1, POT1, TERT promoter)¹
panel Melanoma, extensive (CDKN2A, CDK4, MITF p.(Glu318Lys), BAP1, POT1, TERT promoter)¹
Skin disorders panel¹

Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks

Method